|
CA2328457A1
(en)
|
1998-06-20 |
1999-12-29 |
Washington University |
Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
|
|
IL127773A0
(en)
|
1998-12-28 |
1999-10-28 |
Yeda Res & Dev |
Saccharide conjugates and pharmaceutical compositions comprising them
|
|
SE0201863D0
(en)
|
2002-06-18 |
2002-06-18 |
Cepep Ab |
Cell penetrating peptides
|
|
US9740817B1
(en)
|
2002-10-18 |
2017-08-22 |
Dennis Sunga Fernandez |
Apparatus for biological sensing and alerting of pharmaco-genomic mutation
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
US7468418B2
(en)
|
2003-04-29 |
2008-12-23 |
Avi Biopharma., Inc. |
Compositions for enhancing transport of molecules into cells
|
|
WO2005042539A1
(en)
|
2003-10-29 |
2005-05-12 |
Sonus Pharmaceuticals, Inc. |
Tocopherol-modified therapeutic drug compounds
|
|
EP2933332A1
(en)
|
2004-06-28 |
2015-10-21 |
The University Of Western Australia |
Antisense oligonucleotides for inducing exon skipping and methods of use thereof
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
IE20060565A1
(en)
|
2006-07-28 |
2008-02-06 |
Eurand Pharmaceuticals Ltd |
Drug delivery system based on regioselectively amidated hyaluronic acid
|
|
US20080311040A1
(en)
|
2007-03-06 |
2008-12-18 |
Flagship Ventures |
METHODS AND COMPOSITIONS FOR IMPROVED THERAPEUTIC EFFECTS WITH siRNA
|
|
US20080306001A1
(en)
|
2007-04-04 |
2008-12-11 |
Anzelika Liik |
Transcriptional modulation of extracellular matrix (ecm) of dermal fibroblasts
|
|
WO2009005793A2
(en)
|
2007-06-29 |
2009-01-08 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
ES2639852T3
(es)
|
2007-10-26 |
2017-10-30 |
Academisch Ziekenhuis Leiden |
Medios y métodos para contrarrestar los trastornos musculares
|
|
EP2249851B1
(en)
|
2008-02-13 |
2015-04-01 |
Kao Corporation |
Method for producing hippocastanaceae plant seed extract
|
|
WO2009144481A2
(en)
|
2008-05-30 |
2009-12-03 |
Isis Innovation Limited |
Conjugates for delivery of biologically active compounds
|
|
WO2009147368A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
BR122020021379B1
(pt)
|
2008-10-24 |
2021-05-11 |
Sarepta Therapeutics, Inc. |
oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
|
|
AU2009310557B2
(en)
|
2008-10-27 |
2014-09-11 |
Academisch Ziekenhuis Leiden |
Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
TR201816523T4
(tr)
|
2009-11-12 |
2018-11-21 |
Univ Western Australia |
Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
|
|
EP2394665A1
(en)
|
2010-06-14 |
2011-12-14 |
F. Hoffmann-La Roche AG |
Cell-penetrating peptides and uses therof
|
|
RU2556800C2
(ru)
|
2010-06-14 |
2015-07-20 |
Ф.Хоффманн-Ля Рош Аг |
Пептиды, проникающие в клетки, и их применения
|
|
EP2595663A4
(en)
|
2010-07-19 |
2014-03-05 |
Isis Pharmaceuticals Inc |
MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
EP2646459B1
(en)
|
2010-12-02 |
2020-01-08 |
Bionor Immuno AS |
Peptide scaffold design
|
|
WO2012090150A2
(en)
|
2010-12-27 |
2012-07-05 |
Compugen Ltd |
New cell-penetrating peptides and uses thereof
|
|
CA3092114A1
(en)
|
2011-05-05 |
2012-11-08 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
US9161948B2
(en)
*
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
CN103998458B
(zh)
*
|
2011-08-30 |
2018-10-09 |
医学研究理事会 |
具有中央疏水域的细胞穿透肽
|
|
AU2012308320C1
(en)
|
2011-09-14 |
2018-08-23 |
Translate Bio Ma, Inc. |
Multimeric oligonucleotide compounds
|
|
MX2014014464A
(es)
|
2012-06-26 |
2015-02-12 |
Hoffmann La Roche |
Peptidos penetrantes de celulas y metodos para identificar peptidos penetrantes de celulas.
|
|
EP2895499B1
(en)
|
2012-09-13 |
2019-04-10 |
Université de Genève |
Cell penetrating peptides
|
|
US20150247141A1
(en)
|
2012-09-14 |
2015-09-03 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotide compounds
|
|
EP2900821B1
(en)
|
2012-09-25 |
2020-04-01 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
US20140315977A1
(en)
|
2013-03-14 |
2014-10-23 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
GB201314411D0
(en)
*
|
2013-08-12 |
2013-09-25 |
Medical Res Council |
Peptide conjugates
|
|
BR112016016400A2
(pt)
|
2014-01-16 |
2017-10-03 |
Wave Life Sciences Ltd |
Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
|
|
CA2935426C
(en)
|
2014-01-30 |
2023-07-25 |
F. Hoffmann-La Roche Ag |
Polyoligomer compound with biocleavable conjugates for reducing or inhibiting expression of a nucleic acid target
|
|
WO2015161255A1
(en)
|
2014-04-18 |
2015-10-22 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
|
|
RU2708237C2
(ru)
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
GB201421379D0
(en)
|
2014-12-02 |
2015-01-14 |
Isis Innovation Ltd And Medical Res Council |
Molecule
|
|
EP3034074A1
(en)
|
2014-12-18 |
2016-06-22 |
Universitat De València, Estudi General |
Compound for treatment of myotonic dystrophy type 1
|
|
US10017542B2
(en)
|
2015-03-23 |
2018-07-10 |
Riptide Bioscience, Inc. |
Antimicrobial peptides and methods of use thereof
|
|
JP6817288B2
(ja)
|
2015-08-10 |
2021-01-20 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
新規な連結体及び生体分子と薬物との特異的共役におけるその使用
|
|
US10858410B2
(en)
|
2015-08-12 |
2020-12-08 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier
|
|
EP3858993A1
(en)
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
CN109640961B
(zh)
|
2016-06-01 |
2021-11-02 |
施维雅知识产权英国有限公司 |
聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
|
|
WO2018053316A1
(en)
|
2016-09-15 |
2018-03-22 |
The Regents Of The University Of California |
Improved hybrid telodendrimers
|
|
US20200131231A1
(en)
|
2017-02-17 |
2020-04-30 |
Oxford University Innovation Limited |
Cell penetrating peptides
|
|
WO2019067979A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
WO2019067981A1
(en)
|
2017-09-28 |
2019-04-04 |
Sarepta Therapeutics, Inc. |
POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
|
|
EP3687547A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
US12465646B2
(en)
|
2018-12-07 |
2025-11-11 |
Oxford University Innovation Limited |
Linkers
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
JP2022536495A
(ja)
|
2019-06-19 |
2022-08-17 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを治療する方法
|
|
EP3997228A4
(en)
|
2019-07-09 |
2024-05-15 |
The Governors of the University of Alberta |
SKIP OF EXONS 45 TO 55 USING MUTATION-ADAPTED COCKTAILS, OF ANTISENS MORPHOLINOS, IN THE DMD GENE
|
|
GB201911403D0
(en)
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
WO2022171972A1
(en)
|
2021-02-12 |
2022-08-18 |
Oxford University Innovation Limited |
Cell-penetrating peptide conjugates and methods of their use
|
|
WO2022192749A2
(en)
|
2021-03-12 |
2022-09-15 |
Pepgen Inc. |
Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates
|
|
EP4304657A4
(en)
|
2021-03-12 |
2026-04-01 |
Pepgen Inc |
METHODS OF TREATMENT OF TYPE 1 MYOTONIC DYSTROPHY USING PEPTIDE-OLIGONUCLEOTIDE CONJUGATES
|